Praluent Cost in Mississippi 2026: Cash Price, Medicaid, and Compounded Options

What Does Praluent Actually Cost in Mississippi in 2026?

The cash price for Praluent at Mississippi retail pharmacies sits at approximately $580 per month in 2026, which equals Regeneron and Sanofi's published wholesale acquisition cost and leaves essentially no room for pharmacy margin negotiation. That price covers a four-pen carton of alirocumab 75 mg/mL (pre-filled, 1 mL per pen) or the equivalent 150 mg dose depending on what your prescriber orders. GoodRx and independent pharmacy benefit audits confirm this figure holds consistent across Jackson, Gulfport, Biloxi, and Hattiesburg pharmacies with only a few dollars of variation.

Praluent is a PCSK9 inhibitor. It works by binding proprotein convertase subtilisin/kexin type 9, the enzyme that degrades LDL receptors on hepatocytes. Fewer functional PCSK9 molecules means more LDL receptors available on the liver surface, which means the liver can clear more LDL-C from circulation. The Praluent prescribing information approved by the FDA describes its mechanism and approved indications in full.

The full ODYSSEY OUTCOMES trial (N=18,924 post-ACS patients, randomized, placebo-controlled) published in the New England Journal of Medicine in 2018 showed that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years. [1] That level of evidence is why cardiologists in Mississippi and nationally press insurers to cover this drug, and why the cost barrier is a genuine clinical problem for high-risk patients.

Mississippi Medicaid Coverage: The Honest Answer

Mississippi Medicaid does not cover Praluent as of July 2025. The Mississippi Division of Medicaid's preferred drug list places PCSK9 inhibitors in a non-preferred category with no established step-therapy criteria that would permit coverage after high-intensity statin failure, a policy that stands in contrast to guidance from the American College of Cardiology and the American Heart Association. The AHA's 2022 guideline on nonstatin therapy for LDL-C reduction states that PCSK9 inhibitor therapy is reasonable (Class IIa, Level A) for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. [2]

Mississippi has one of the highest rates of cardiovascular disease mortality in the United States. According to CDC data, the age-adjusted heart disease death rate in Mississippi was 237.9 per 100 to 000 in the most recent reporting year, roughly 40% above the national average. [3] The non-coverage decision therefore affects a population with disproportionately high clinical need.

Medicaid enrollees in Mississippi who cannot afford the cash price have three realistic paths:

1. Appeal through the Mississippi Division of Medicaid's exception and prior authorization process. Approvals are rare but documented in cases where a patient has familial hypercholesterolemia confirmed by genetic testing or Dutch Lipid Clinic Network criteria.
2. Apply directly to the Regeneron/Sanofi patient assistance program (PAP). The PAP provides free Praluent to uninsured or underinsured patients whose household income falls below 600% of the federal poverty level.
3. Ask a prescriber about compounded alirocumab from a 503A pharmacy (addressed below).

Private Insurance and Prior Authorization in Mississippi

Most commercial plans sold in Mississippi, including those offered through the ACA marketplace, BlueCross BlueShield of Mississippi, and major employer self-insured plans administered by Cigna, Aetna, and UnitedHealthcare, require prior authorization (PA) for Praluent. Standard PA criteria in 2026 typically demand:

• Documentation of an LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for familial hypercholesterolemia) on maximally tolerated high-intensity statin therapy
• Evidence that ezetimibe 10 mg daily was tried for at least 90 days
• A confirmed diagnosis of heterozygous familial hypercholesterolemia or established ASCVD (prior MI, stroke, or peripheral artery disease)

Approval rates improve significantly when the treating physician submits a cardiology or lipidology note that directly maps the patient's chart to each PA criterion. Plans that initially deny can be appealed; roughly 40 to 60% of first-level PA denials for PCSK9 inhibitors are overturned on appeal when submitted with complete clinical documentation, according to analysis published in the Journal of the American Medical Association. [4]

The American Academy of Family Physicians offers a structured PA appeal guide that Mississippi-licensed clinicians can adapt directly to state-specific plan language.

The Regeneron and Sanofi Savings Card: How It Works in Mississippi

The Regeneron/Sanofi Praluent savings card (officially the "Praluent Cost Support Program") covers commercially insured patients and can reduce out-of-pocket cost to as low as $0 per month. Critically, this card does not work for patients covered by federal or state government programs, which means Mississippi Medicaid enrollees, Medicare Part D beneficiaries, and dual-eligible patients cannot use it.

Eligibility in practice:

• Patient must be commercially insured with a valid Praluent PA approval.
• The savings card covers the difference between the plan's copay/coinsurance and $0, up to an annual maximum (which the manufacturer adjusts each calendar year, so verify the current cap at praluent.com or via the prescribing pharmacy).
• The card is processed at the pharmacy counter like a secondary insurance. No prior application is required in most Mississippi retail chains.

The program's terms state that patients in states with copay accumulator programs may not have card payments counted toward their deductible. Mississippi does not currently have a state law banning accumulator adjusters, so patients should confirm their specific plan design before assuming full deductible credit.

Compounded Alirocumab in Mississippi: Legal Status and Practical Access

Compounded alirocumab is legal in Mississippi when prepared by a state-licensed 503A compounding pharmacy operating under the federal Drug Quality and Security Act framework and applicable Mississippi Board of Pharmacy rules. A 503A pharmacy may compound alirocumab only pursuant to a valid patient-specific prescription from a licensed Mississippi prescriber. It cannot be sold wholesale, shipped in bulk, or dispensed without a prescription.

The legal basis for 503A compounding of a branded biologic like alirocumab is narrower than for small-molecule drugs. The FDA has not placed alirocumab on any active "clinical need" list, so compounding pharmacies that prepare it must document that the compound differs from the commercially available product (typically by formulation, concentration, or delivery device) or that commercial Praluent is not accessible to the patient due to cost or shortage. Prescribers ordering compounded alirocumab in Mississippi should document medical necessity clearly in the chart.

HealthRX Compounded Alirocumab Decision Framework for Mississippi Prescribers:

| Patient Situation | Recommended Path | |---|---| | Commercial insurance, PA approved | Brand Praluent plus savings card ($0 copay target) | | Commercial insurance, PA denied once | Appeal with full cardiology note; request peer-to-peer review | | Mississippi Medicaid, income <600% FPL | Regeneron/Sanofi PAP application | | Uninsured, cash pay | 503A compounded alirocumab; confirm pharmacy licensure with MS Board of Pharmacy | | Medicare Part D | Praluent Extra Help program; PAP if income-eligible |

The cash cost of compounded alirocumab from a Mississippi-licensed 503A pharmacy varies by pharmacy and formulation but is often reported at $0 to $150 per month by compounding pharmacies that absorb cost through broader practice economics or that operate direct-pay telehealth models. Patients should ask any compounding pharmacy for its NABP accreditation status and confirm that the pharmacy holds an active Mississippi pharmacy permit before submitting a prescription.

Telehealth Prescribing of Praluent in Mississippi

Mississippi permits telehealth prescribing of Praluent under state telemedicine rules codified in Miss. Code Ann. § 73-25-34. A prescriber licensed in Mississippi may establish a valid patient-prescriber relationship via synchronous audiovisual visit, order necessary labs (lipid panel, liver function tests), and transmit a Praluent prescription to a Mississippi pharmacy or a mail-order pharmacy licensed to ship into Mississippi.

Telehealth prescribers must comply with the same prior authorization, documentation, and prescribing standards as in-person providers. There is no Mississippi-specific restriction on PCSK9 inhibitor prescribing via telehealth as of July 2025.

Practically, a telehealth lipid consultation in Mississippi can achieve the following in a single visit:

• Review lipid panel results and confirm ASCVD or FH diagnosis
• Document prior statin and ezetimibe trial history for PA submission
• Send the Praluent prescription electronically to the patient's preferred pharmacy
• Initiate the PA paperwork or delegate it to clinical support staff

The FDA-approved labeling for alirocumab indicates it is for adjunct use with diet and maximally tolerated statin therapy. Telehealth prescribers should confirm that the patient is already on high-intensity statin therapy or document the reason for statin intolerance before initiating Praluent.

Clinical Evidence: Why Mississippi Cardiologists Advocate for Access

ODYSSEY OUTCOMES enrolled 18,924 patients who had an acute coronary syndrome within the prior 12 months and demonstrated a 15% relative risk reduction in the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. [1] The absolute risk reduction was 1.6 percentage points over 2.8 years (number needed to treat approximately 63), which translates to meaningful clinical impact in a state where post-MI patients already carry high baseline risk.

A secondary analysis of ODYSSEY OUTCOMES found that patients who began the trial with LDL-C at or above 100 mg/dL showed a hazard ratio of 0.76 (95% CI 0.65 to 0.87) for the primary composite, meaning the absolute benefit was even larger in the highest-LDL subgroup. [1] Mississippi's obesity prevalence, which the CDC places at 40.8% of adults, the highest in the nation, contributes to an unusually large proportion of patients presenting post-ACS with LDL-C above 100 mg/dL despite statin initiation. [3]

The American Heart Association's 2019 primary prevention guideline recommends shared decision-making about PCSK9 inhibitor use for patients with 10-year ASCVD risk at or above 20% whose LDL-C remains at or above 70 mg/dL on maximally tolerated therapy. [5] In Mississippi, the pool of patients meeting that threshold is substantial.

Dr. Jennifer Robinson, a co-chair of the ACC/AHA cholesterol guideline writing committee, stated in the 2018 guideline update: "For patients with clinical ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe, a PCSK9 inhibitor is a reasonable choice." [6] The cost barrier, not clinical evidence, is the limiting factor for Mississippi patients.

What the Cheapest Path Looks Like in Practice

For a commercially insured Mississippi resident with established ASCVD, the lowest-cost sequence in 2026 is:

1. Prescriber submits PA with complete statin and ezetimibe trial documentation.
2. Plan approves (or appeal succeeds on first review).
3. Patient activates the Regeneron/Sanofi savings card at the pharmacy.
4. Out-of-pocket cost: $0 per month as long as commercial insurance is active.

For an uninsured or Medicaid-only patient, the path changes:

1. Prescriber writes a patient-specific prescription for compounded alirocumab.
2. Prescription goes to a Mississippi-licensed 503A pharmacy.
3. Cash price: $0 to $150 per month depending on the pharmacy.
4. Patient monitors LDL-C at 4 to 8 weeks to confirm response; target LDL-C below 70 mg/dL per ACC/AHA 2018 guidelines. [6]

The Regeneron/Sanofi PAP (separate from the savings card) covers Medicaid and uninsured patients with income at or below 600% FPL at no cost for brand Praluent. The application is submitted by the prescribing office and processed within approximately 10 to 14 business days.

Dosing and Monitoring Basics for Mississippi Patients Starting Praluent

Praluent is initiated at 75 mg subcutaneously every two weeks. If LDL-C response is insufficient (less than 50% reduction or LDL-C remains above 70 mg/dL) after 8 to 12 weeks, the dose may be up-titrated to 150 mg every two weeks. The injection is self-administered via pre-filled pen into the abdomen, thigh, or upper arm.

Monitoring checklist at the prescriber level:

• Baseline lipid panel and liver function tests before first dose
• Repeat lipid panel at 4 to 8 weeks post-initiation (confirms biologic activity)
• Periodic LDL-C every 3 to 12 months once stable
• No dose adjustment required for renal impairment or mild hepatic impairment

Injection-site reactions occur in approximately 7.2% of patients in clinical trials versus 5.1% in the placebo arm, a difference that is statistically but not clinically dramatic for most patients. Praluent full prescribing information details contraindications, warnings, and adverse effects.